George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Fair point, Potnak.
Aber - I'm always a bit wary of posters using the company name in their moniker.
Lsesar - each time RF requested more shares they will have had to provide evidence that they had sold their previously issued shares and the selling price in order to work out how many more shares they were due. The latest RNS more or less tells us RF had been selling their shares at a loss and have now been given a final number to pay off the remaining balance.
You initially seemed quite positive about the share but now you're throwing some doubt in here, hmmmmmm.
Hi AOTD - I suspect those dates were simply chosen as suitable 'place holders' when completing the trial docs. They would push the dates out far enough to build in any potential slippage since they couldn't possibly know how many volunteers would sign up and when. The last advert looking for recruits was taken off the Nucleus Network website around 6th Jan. so I'd expect them to have enrolled the final subjects by the end of that month.
Hi Eazy - although that would be the sensible thing to do, RF have sold immediately so all notions of 'investing' go out the window. They look as if they need cash to help their rto of another company so rather than playing the long game, I was thinking they might just go for a quick profit and exercise their warrants very soon instead of waiting for the sp to hit £1+.
Thanks all for the swift replies.
SOG - re those initial warrants at 147p, under the terms of the agreement (or 'shafting' to use a more appropriate term), aren't they reduced to 10p due to the subsequent WRAP/Subscription?
I suppose it's all fairly moot now anyway and a potential partner would review all aspects of the company & compound before entering into a deal.
RF dumped their shares as soon as they got them (or even before!) so what are the chances that they'll shortly cash in their warrants to make a quick return now that the sp is over 30p?
Would any prospective partner for 1801 want them out of the picture completely or wouldn't it matter to them?
Any thoughts?
Only posting this to illustrate our compounds are known by at least one big pharma. Whilst the patents only mention 1801/2 in the context of myriad other compounds, at least we're not flying totally under the radar. I came across the patents by searching the WIPO site for anything referencing SDC-1801 and then based on those results, limited it to results with "Gilead or MiroBio" AND "SDC-1801" -
https://patentscope.wipo.int/search/en/result.jsf?_vid=P12-LVCGCV-13961
MiroBio was an Oxford spinout acquired by Gilead for £332m - https://www.ox.ac.uk/news/2022-08-04-oxford-spinout-mirobio-acquired-gilead-sciences-405m
Onwards!
Knew I'd find it somewhere - https://apps.dtic.mil/sti/pdfs/AD1087498.pdf
5. CHANGES/PROBLEMS:
We received a no cost extension for this project in April 2018. The PI on this project, Dr. Abhishek
Trigunaite, had to travel to his home country (India) for immigration related issues (VISA stamping).
Because of the unanticipated length of the processing time, he was required to stay in India for nearly
3 months and only able to return close to the termination date of the project. This loss of effort meant
that we were unable to perform the long-term dosing studies prior to the termination date of the grant.
Additionally, at the beginning of this award we had only proposed to look at only one strain of lupus
prone mice ((NZBxNZW) F1 mice) but later during the scientific review of the proposal, it was
decided to include a second mouse model (MRL/lpr) in the study. This increase in the animal number
for the short term (4-6 week) treatment did not leave us with enough funds to perform a long-term
survival study.
Hi Celtic - the trial was with 1802 and the lead researcher had to return to India due to their visa running out or family issues so the work was never completed.
https://www.pharmiweb.com/press-release/2020-07-24/encouraging-preclinical-results-generated-with-sareum-s-tyk2jak1-inhibitors-in-a-disease-model-of-lupus
I'll try and find the actual project doc on the US Military site.
Hi Aber - I'm not saying the rise is down to Parker at all. All I'm suggesting is a number of shareholders will have made money out of the situation.
If life hands you lemons, squirt lemon juice back in life's eyes.
Even if there's an outside chance of a Monday morning RNS I expect a further surge tomorrow afternoon as FOMO kicks in.
Hi Silver - I wonder how many of the posters who wanted Parker's head on a spike filled up with cheap shares and are now secretly quite grateful for the RF shotfest (typo?) as they are now printing money.
Amazing what more than doubling your cash in 10 days can do for the spirits.
Onwards!
Hi Stick - Revel or Airfix?
(Sorry, couldn't resist)
Hi Bailiff - as long as she didn't get any of your SAR shares then all is well. By any chance is Auckland the furthest point on the globe from Bailiff HQ?
Best wishes.
Quick Bailiff, get Mrs. Bailiff on another cruise!
Evening all - I just hope that the success of the recent WRAP offer (hats off to B-B et al) will open the BoD's eyes and any future fundraise will be available through all major platforms. I'm still miffed that Halifax didn't take part even though I managed to fill my ISA for this year at sub-12p - no pleasing some folk!
Just thinking aloud so apologies if I'm way off the mark -
If the BoD received a glowing report from P1a tomorrow would it be in their interest to delay the news until they'd got shot of RF as much as possible? I know significant news needs to be RNS'd immediately but they could sit on it for a wee while yet under the guise of giving the report full consideration and planning next steps etc. In the meantime RF dump their shares reducing what they are due (excluding warrants). The BoD could then announce the results, ensuring the sp has a chance of a clear run much higher without extended RF sells to hold it back.
Stellar results and a positive Investor Meets presentation telling us all how wonderful 1801 is might go some way to gloss over the RF debacle. Yes, there are still unanswered questions over RF & PH but seeing JR doing cartwheels over his invention would quickly take the sting out of recent events.
Is it fair to presume any recent shorts are now closed? There are a few short trackers on the web but I don't see any evidence PH had a short unless it was below the threshold for declaring it.
https://www.fca.org.uk/markets/short-selling/notification-disclosure-net-short-positions
https://www.investegate.co.uk/company/SAR/short-positions
https://shorttracker.co.uk/company/GB00B02RFS12/
A steady daily climb of 10% will do nicely.
Hi Laz - I can almost imagine a sort of domino effect. RF needed funds to carry out their reverse takeover of SVEN but couldn't raise the cash so their only option was to dump chunks of their portfolio to prop themselves up. That led to the decimation of our sp and a great deal of finger pointing. If the city/AIM weren't in the state they're in then maybe both SAR & RF could've accessed the funding each needed without all the resulting fallout.
I expect we'll never know the real truth of the matter.
Interesting article, George. It echoes another post I put up the other day and gives some support to the notion that the city wasn't keen to help us raise funds thereby leading to the RF situation.